Real-World study reveals how alprolix controls bleeding in hemophilia b
NCT ID NCT03901755
First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study followed 151 people with hemophilia B for 24 months to see how well Alprolix works in real-world settings. Researchers tracked bleeding episodes, how often the medicine was used, and the amount needed. The goal was to understand the drug's effectiveness and usage patterns outside of a controlled clinical trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Swedish Orphan Biovitrum Research Site
Brno, Czechia
-
Swedish Orphan Biovitrum Research Site
Prague, Czechia
-
Swedish Orphan Biovitrum Research Site
Dublin, Ireland
-
Swedish Orphan Biovitrum Research Site
Bari, Italy
-
Swedish Orphan Biovitrum Research Site
Florence, Italy
-
Swedish Orphan Biovitrum Research Site
Genova, Italy
-
Swedish Orphan Biovitrum Research Site
Milan, Italy
-
Swedish Orphan Biovitrum Research Site
Roma, Italy
-
Swedish Orphan Biovitrum Research Site
Turin, Italy
-
Swedish Orphan Biovitrum Research Site
Oslo, Norway
-
Swedish Orphan Biovitrum Research Site
Murcia, Spain
-
Swedish Orphan Biovitrum Research Site
Vigo, Spain
-
Swedish Orphan Biovitrum Research Site
Gothenburg, Sweden
-
Swedish Orphan Biovitrum Research Site
Malmö, Sweden
-
Swedish Orphan Biovitrum Research Site
Hull, United Kingdom
-
Swedish Orphan Biovitrum Research Site
London, NW3 2QG, United Kingdom
-
Swedish Orphan Biovitrum Research Site
London, SE1 7EH, United Kingdom
-
Swedish Orphan Biovitrum Research Site
London, W12 0HS, United Kingdom
-
Swedish Orphan Biovitrum Research Site
London, WC1N 3JH, United Kingdom
-
Swedish Orphan Biovitrum Research Site
Manchester, United Kingdom
-
Swedish Orphan Biovitrum Research Site
Oxford, United Kingdom
-
Swedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital)
Athens, Greece
-
Swedish Orphan Biovitrum Research Site (Hospital Sant Joan de Deu)
Barcelona, Spain
-
Swedish Orphan Biovitrum Research Site (Hospital de Vall d'Hebrón)
Barcelona, Spain
-
Swedish Orphan Biovitrum Research Site (Karolinska University Hospital adult)
Stockholm, Sweden
-
Swedish Orphan Biovitrum Research Site (Karolinska University Hospital pediatric)
Stockholm, Sweden
-
Swedish Orphan Biovitrum Research Site (King Faisal Hospital adult)
Riyadh, Saudi Arabia
-
Swedish Orphan Biovitrum Research Site (King Faisal Hospital pediatric)
Riyadh, Saudi Arabia
-
Swedish Orphan Biovitrum Research Site (Laikο General Hospital of Athens)
Athens, Greece
Conditions
Explore the condition pages connected to this study.